Is treatment with a luteinizing hormone-releasing hormone agonist justified in short adolescents?

New England Journal of Medicine

Volumn 348, Issue 10, 2003, Pages 942-945

  Lee, Mary M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GONADORELIN AGONIST; GROWTH HORMONE; LUTEINIZING HORMONE; SEX HORMONE;

BONE DENSITY; BONE MINERAL; COGNITIVE DEFECT; DEPRESSION; DRUG COST; EDITORIAL; GONADOTROPIN RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; OSTEOPENIA; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROSTATE CANCER; PULSATILE HORMONE RELEASE; SHORT STATURE;

PROFESSIONAL PATIENT RELATIONSHIP;

ADOLESCENT; BODY HEIGHT; BONE DENSITY; CHILD; ENZYME INHIBITORS; GONADOTROPIN-RELEASING HORMONE; GROWTH DISORDERS; HUMANS; PUBERTY; TRIPTORELIN;

EID: 0037422021     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe030003     Document Type: Editorial

References (15)

1. Wilkins L. The need for an inhibitor of gonadotropin. J Clin Endocrinol Metab 1953;13:739-41.
2. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981;52:370-2.
3. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978;202:631-3.
4. Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908-17.
5. Carel JC, Hay F, Coutant R, Rodrigue D, Chaussain JL. Gonadotropin-releasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development. J Clin Endocrinol Metab 1996;81:3318-22.
6. Lindner D, Job JC, Chaussain JL. Failure to improve height prediction in short-stature pubertal adolescents by inhibiting puberty with luteinizing hormone-releasing hormone analogue. Eur J Pediatr 1993;152:393-6.
7. Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 1996;81:1152-5.
8. Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44-9.
9. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480-8.
10. Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90:427-32.
11. Sandberg DE, Brook AE, Campos SP. Short stature: a psychosocial burden requiring growth hormone therapy? Pediatrics 1994;94:832-40.
12. Downie AB, Mulligan J, Stratford RJ, Betts PR, Voss LD. Are short normal children at a disadvantage? The Wessex growth study. BMJ 1997;314:97-100.
13. Downie AB, Mulligan J, McCaughey ES, Stratford RJ, Betts PR, Voss LD. Psychological response to growth hormone treatment in short normal children. Arch Dis Child 1996;75:32-5.
14. Allen DB, Brook CG, Bridges NA, Hindmarsh PC, Guyda HJ, Frazier D. Therapeutic controversies: growth hormone (GH) treatment of non-GH deficient subjects. J Clin Endocrinol Metab 1994;79:1239-48.
15. Lantos J, Siegler M, Cuttler L. Ethical issues in growth hormone therapy. JAMA 1989;261:1020-4.